Barely Significant
← all excerpts

PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses.

Pharmacotherapy · 2016 · PMC5071694 · PMID 26822752

Europe PMCDOI
1
hedged sentence
0.0790
closest p · 1.6× alpha
0.0790
boldest claim

The sentences

a nonsignificant trendp=0.079so close (0.05 < p ≤ 0.1)
A study of atezolizumab across multiple tumor types found a significant association between treatment response and tumor‐infiltrating immune cell PD‐L1 expression (p=0.007) but a nonsignificant trend between response and tumor cell PD‐L1 expression (p=0.079). 47 There was also a trend for increased PFS with increasing PD‐L1 expression by tumor‐infiltrating immune cells; however, further studies are needed in this area.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.